Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 32.07% is 53% above its 4-year average of 21.02%, near the low end of its 4-year range (10.76%–103.00%).
2.90% above its 12-month average of 31.17%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 14.21%.
EBITDA MARGIN
32.07%
EBITDA MARGIN AVG TTM
31.17%
EBITDA MARGIN AVG 3Y
19.02%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.90%
CURRENT VS 3Y AVG
+68.64%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Solventum Corporation
Market Cap
$15.14B
EBITDA Margin
32.07%
TTM Avg
31.17%
3Y Avg
19.02%
5Y Avg
N/A
Market Cap
$16.40B
EBITDA Margin
22.25%
TTM Avg
22.41%
3Y Avg
21.18%
5Y Avg
20.68%
Market Cap
$13.40B
EBITDA Margin
22.69%
TTM Avg
18.62%
3Y Avg
20.95%
5Y Avg
21.80%
Market Cap
$12.30B
EBITDA Margin
5.99%
TTM Avg
7.75%
3Y Avg
3.55%
5Y Avg
8.89%
Market Cap
$18.09B
EBITDA Margin
29.84%
TTM Avg
29.78%
3Y Avg
28.27%
5Y Avg
25.91%
Market Cap
$12.07B
EBITDA Margin
23.27%
TTM Avg
22.46%
3Y Avg
26.66%
5Y Avg
22.37%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $15.14B | 32.07% | 31.17% | 19.02% | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.11B | 38.84% | 34.03% | 26.26% | 22.70% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 22.25% | 22.41% | 21.18% | 20.68% |
| Revvity, Inc. (RVTY)vs › | $13.87B | 23.07% | 26.75% | 30.05% | 32.80% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.40B | 22.69% | 18.62% | 20.95% | 21.80% |
| Penumbra, Inc. (PEN)vs › | $12.52B | 14.73% | 11.96% | 9.26% | 5.60% |
| Baxter International Inc. (BAX)vs › | $12.30B | 5.99% | 7.75% | 3.55% | 8.89% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 29.84% | 29.78% | 28.27% | 25.91% |
| Encompass Health Corporation (EHC)vs › | $12.07B | 23.27% | 22.46% | 26.66% | 22.37% |
| DaVita Inc. (DVA)vs › | $11.66B | 19.98% | 20.97% | 19.78% | 20.10% |
Gross Margin
54.7%
EBITDA Margin
32.1%
Operating Margin
25.0%
Net Margin
17.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 14.21% |
| 2026-03-31 | 10.76% |
| 2025-12-31 | 103.00% |
| 2025-09-30 | 12.31% |
| 2025-06-30 | 15.55% |
| 2025-03-31 | 13.57% |
| 2024-12-31 | 13.78% |
| 2024-09-30 | 19.60% |
| 2024-06-30 | 18.12% |
| 2024-03-31 | 25.79% |
| 2023-12-31 | 26.77% |
| 2023-09-30 | 31.24% |
| 2023-06-30 | 26.49% |
| 2023-03-31 | 25.36% |
| 2022-12-31 | 18.83% |
| 2022-09-30 | 28.12% |
| 2022-06-30 | 28.43% |
| 2022-03-31 | 28.43% |
